Brano Therapeutics
Singapore, Singapore
About Brano Therapeutics
Singapore-based biotech spin-off from Duke-NUS Medical School developing small-molecule inhibitors for cardio-metabolic diseases. Its lead asset targets impaired cardiac nutrient processing in Heart Failure with preserved Ejection Fraction (HFpEF), a condition with rising prevalence and limited approved therapies. The company operates under a Duke-NUS licensing agreement and aims to enter clinical trials by 2029.
Latest Funding
SeedAnnounced 2026-05-06
Buying Signals
Where the capital is going, and whether it's already started moving.
Spend Intent
4 signals · where the capital is going
Build out drug-discovery, translational biology, and clinical operations team in Singapore Science Park to support pipeline progression and licensed Duke-NUS te…
inferred from biotech seed stage + Singapore HQ
Operate Duke-NUS licensing agreement, manage academic collaborations (e.g. University of Cincinnati), and run lab/office at Singapore Science Park.
technode.global
+2 more capital deployment signals · confidence ratings · source articles
Sign up freeIn the news
Selling to Brano Therapeutics? You're in the right place.
Knowing they raised is the start. The edge is what's attached to Brano Therapeutics.
Spend intent
Where this round will be spent.
Hiring signals
Which departments are growing.
Verified contacts
Who actually decides.
No credit card. Five minutes, no approvals.
Ask AI
What is the unique value proposition of Brano Therapeutics, and who are their main competitors?
Sign up free to ask AI about Brano Therapeutics
Our AI has read their website, news, and funding history. 25 credits included with every free account.
Sign up free: 25 credits includedAuto-matched to your ICP
Every company, scored against your profile. Automatically.
Industry
High
Size
Mid
Stage
High
Match score blends industry, company size, growth stage, tech stack, and geography. The moment you set your ICP, every company in our database gets scored.
Investors
SEEDS
Lead investor · Seed
Key Highlights
AI InsightsSpin-off from Duke-NUS Medical School targeting Heart Failure with preserved Ejection Fraction (HFpEF), a condition with limited approved therapies and a rising prevalence driven by ageing populations and diabetes/hypertension comorbidities.
AI reads their website, press releases, and funding context to surface what makes them unique - so you tailor your pitch before the first call.
Try it free →Generates a personalized cold email based on their funding round, capital deployment signals, and company context. Ready to send in under 10 seconds.
Try it free →Short, personalized connection request crafted around their recent funding and what your product can help them achieve with it.
Try it free →Maps their competitive landscape with AI - invaluable context before your first call and for positioning your pitch against their alternatives.
Try it free →Extracts capital deployment signals from their funding news - reach out knowing exactly where they're investing and why your product fits.
Try it free →Similar Companies
Discover companies similar to Brano Therapeutics
Selling to Brano Therapeutics? You're in the right place.
Knowing they raised is the start. Our difference is what comes attached to Brano Therapeutics.
Spend Intent
Where this round will be spent.
Hiring Signals
Which departments are growing.
Verified Contacts
Who actually decides.
No credit card. Five minutes, no approvals.
Free weekly newsletter on startup funding.
20 rounds, ranked by amount. Industry and stage breakdowns. A short market note. One email, free, no noise. 2,000+ subscribers.
No spam, ever. Unsubscribe with one click.